Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study)

BACKGROUND: Nivolumab plus ipilimumab combination therapy is one of the standard therapies for untreated renal cell carcinoma patients with an International Metastatic Renal Cell Carcinoma Database Consortium intermediate/poor risk. We have previously reported the 1-year analysis results of the effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kojima, Takahiro, Kato, Renpei, Sazuka, Tomokazu, Yamamoto, Hayato, Fukuda, Shohei, Yamana, Kazutoshi, Nakaigawa, Noboru, Sugino, Yusuke, Hamamoto, Shuzo, Ito, Hiroaki, Murakami, Hiroshi, Obara, Wataru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631464/
https://www.ncbi.nlm.nih.gov/pubmed/35920793
http://dx.doi.org/10.1093/jjco/hyac124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631464/
https://www.ncbi.nlm.nih.gov/pubmed/35920793
http://dx.doi.org/10.1093/jjco/hyac124

Ejemplares similares